Get the Stockscreener App
10.50
1.25%
0.13
After Hours:
10.50
Valneva Se Adr stock is traded at $10.50, with a volume of 17,285.
It is up +1.25% in the last 24 hours and up +17.45% over the past month.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
See More
Previous Close:
$10.37
Open:
$10.57
24h Volume:
17,285
Relative Volume:
0.19
Market Cap:
$902.24M
Revenue:
$213.45M
Net Income/Loss:
$-72.46M
P/E Ratio:
-10.57
EPS:
-0.9936
Net Cash Flow:
$-47.28M
1W Performance:
-4.72%
1M Performance:
+17.45%
6M Performance:
+66.93%
1Y Performance:
+86.50%
1-Day Range:
$10.37
$10.60
1-Week Range:
$10.31
$11.35
52-Week Range:
$3.62
$12.25
Valneva Se Adr Stock (VALN) Company Profile
Compare VALN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VALN
Valneva Se Adr
|
10.50 | 890.42M | 213.45M | -72.46M | -47.28M | -0.9936 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Valneva Se Adr Stock (VALN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Resumed | H.C. Wainwright | Buy |
| Aug-03-22 | Initiated | H.C. Wainwright | Buy |
Valneva Se Adr Stock (VALN) Latest News
Valneva (NASDAQ:VALN) Stock Price Down 4.9%Here's Why - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SEVALN - Your Wyoming Link
Valneva–Aktie: Finanzierung gesichert, Erwartungen gesenkt! - Finanztrends
Valneva (NASDAQ:VALN) Shares Gap DownWhat's Next? - MarketBeat
Valneva stock falls after FDA suspension forces guidance cut - Investing.com
VALNEVA Déclaration d’actions et de droits de vote : 30 septembre 2025 - GlobeNewswire Inc.
Valneva (NASDAQ:VALN) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Valneva (NASDAQ:VALN) Shares Gap UpHere's What Happened - MarketBeat
VALNEVA ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Valneva SE Sponsored ADR (NASDAQ:VALN) Short Interest Update - MarketBeat
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Valneva (NASDAQ:VALN) Trading 5.6% HigherShould You Buy? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Valneva SE Sponsored ADR (NASDAQ:VALN) Short Interest Down 81.3% in August - Defense World
Valneva SE Sponsored ADR (NASDAQ:VALN) Short Interest Up 64.6% in August - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Louisiana First News
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Investors to Connect - ACCESS Newswire
Guggenheim lowers Valneva stock price target to $13 on Ixchiq BLA suspension - Investing.com
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Investors to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Investors to Reach Out - ACCESS Newswire
Valneva announces U.S. FDA’s decision to suspend license of IXCHIQ - MSN
Valneva selloff on FDA suspension overdone, says H.C. Wainwright - MSN
Valneva SE ADR: Rising -26.86% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
Valneva price target lowered to $14 from $18 at Jefferies - MSN
HC Wainwright Forecasts Valneva's Q3 Earnings (NASDAQ:VALN) - MarketBeat
Jefferies lowers Valneva stock price target to $14 on FDA suspension - Investing.com
Valneva stock tumbles as FDA suspends license for IXCHIQ vaccine By Investing.com - Investing.com South Africa
Valneva stock tumbles as FDA suspends license for IXCHIQ vaccine - Investing.com
Valneva Se Adr Stock (VALN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):